scholarly article | Q13442814 |
P356 | DOI | 10.1089/10430340050207957 |
P698 | PubMed publication ID | 11119418 |
P2093 | author name string | Fong Y | |
Kooby DA | |||
Petrowsky H | |||
Hawkins WG | |||
Zager JS | |||
Johnson P | |||
Bennett JJ | |||
Burt BM | |||
Delman KA | |||
Horsburgh BC | |||
McAuliffe PF | |||
P433 | issue | 18 | |
P921 | main subject | oncolytic virus | Q1560099 |
P304 | page(s) | 2465-2472 | |
P577 | publication date | 2000-12-01 | |
P1433 | published in | Human Gene Therapy | Q15757580 |
P1476 | title | Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy | |
P478 | volume | 11 |
Q33713249 | A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer |
Q39557591 | Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. |
Q35043106 | Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes |
Q37132189 | Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice |
Q78392743 | Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer |
Q54714678 | Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. |
Q37099738 | Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters |
Q35131235 | Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells |
Q45731236 | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer |
Q91521080 | Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model |
Q35116166 | Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer |
Q35126267 | Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review |
Q36444443 | Herpes simplex virus 1 (HSV-1) for cancer treatment |
Q81444939 | Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy |
Q33713824 | Herpes simplex virus oncolytic therapy for pediatric malignancies |
Q38500301 | Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy |
Q35699072 | ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN. |
Q37899230 | Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress |
Q35216661 | Oncolytic herpes simplex virus for tumor therapy |
Q28202611 | Oncolytic herpes simplex virus vectors for cancer virotherapy |
Q35613495 | Oncolytic herpes viruses as a potential mechanism for cancer therapy. |
Q35832074 | Oncolytic virotherapy for advanced liver tumours. |
Q36769180 | Oncolytic viruses in cancer therapy |
Q36109704 | Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. |
Q24633957 | Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver |
Q44124151 | Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene |
Q37759934 | Regional liver therapy using oncolytic virus to target hepatic colorectal metastases |
Q36086213 | Replication-Competent Controlled Herpes Simplex Virus |
Q37596491 | Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice |
Q41919532 | Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses |
Q45733718 | The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma |
Q34423157 | Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta |
Q36920216 | Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. |
Q33976318 | VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy |
Q45880904 | Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors |
Q64378232 | Viral oncolysis |
Q39786869 | Viral vector-induced expression of bone morphogenetic protein 2 produces inhibition of tumor growth and bone differentiation of stem cells |
Search more.